Leadership
Novartis president, development and chief medical officer talks about the pivotal role of the development India hub in progressing breakthrough drugs, how AI is delivering gains in the trials arena, driving focus in the R&D engine and the Swiss group’s approach in the obesity space.
Parexel's CEO Peyton Howell and India boss Sanjay Vyas talk to Scrip about the value of clinical trial diversity, AI pilots underway and opportunities for India amid geopolitical rumblings, as well as the need for standardized regulatory approaches to enhance sponsor interest.
President Trump's Executive Order creating the commission does not mention vaccines, which Kennedy has criticized.
CEO Mike Exton talked to Scrip about moving the company forward after a disappointingly disruptive 2024.
The founder and director of City Therapeutics and founding CEO of Alnylam discussed pressing issues facing the biotech sector in a fireside chat at the recent BIO CEO & Investor Conference.
The CEO of Korean biotech Bridge Biotherapeutics shares progress and strategy for its lead candidate for IPF, along with thoughts on what Trump and the ongoing Korean political crisis might mean for the industry.
Highlights from the BIO CEO & Investor Conference, held in New York 10-11 February, include the impact of US political changes, Chinese companies entering the obesity race, and IPO pitfalls.
CEO Christopher Viehbacher has said repeatedly that Biogen will build its pipeline internally and through deals, and Grogan reshuffled the research organization with that in mind.
Recent moves in the industry include C-suite changes at Ironwood Pharmaceuticals and Procaps Group, plus Viracta Therapeutics acquires chief executive officer from Molecular Templates.
Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.
Lilly’s revenue is rising rapidly based on its successes in diabetes and obesity, and the company is reinvesting in big plays in those markets as well as in cancer, lipid-lowering and other indications.
Novartis enjoyed exceptional growth in 2024, and its US leader, Victor Bulto, puts that down to greater R&D and commercial co-ordination paying off with drugs such as Kisqali in early breast cancer.
Recent moves in the industry include changes at the top at Shanghai Bao Pharmaceutical and Alumis, plus Nurix Therapeutics acquires chief commercial officer from Arvinas.
Health and Human Services Department Secretary nominee Robert F. Kennedy Jr. falsely said prescription drugs are the third leading cause of death and made other comments on corporate capture, mifepristone, anti-depressants, and ADHD treatments, suggesting someone who often sows doubt and misleads on the risk-benefit balance of pharmaceuticals.
Leading Japanese pharma firm names first ever woman chief exec as it reports a jump in operating profit in the fiscal nine months, led by Entyvio.
HHS Secretary nominee Robert F. Kennedy Jr. discussed the Trump Administration's support for Medicare price negotiation during his confirmation hearing.
The year is off to a good start for the Japanese pharma with back-to-back approvals in the US. CEO Ken Keller talked to Scrip about some recent setbacks and looking ahead.
Continuing to grow Nuplazid and Daybue are top priorities along with pipeline and business development, Catherine Owen Adams told Scrip.
Recent moves in the industry include C-suite changes at Ribometrix and Emyria, plus Arvinas acquires chief commercial officer from Lexicon Pharmaceuticals.
The TYK2 inhibitor is in Phase III development for plaque psoriasis and psoriatic arthritis but the company said it will not pursue late-stage studies in lupus, partly due to the Inflation Reduction Act.